GLS-5310 is under clinical development by GeneOne Life Science and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GLS-5310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GLS-5310 overview

GLS-5310 is under development for the prevention of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine is administered through both intradermal route and intranasal route.

GeneOne Life Science overview

GeneOne Life Science (GeneOne) is a biotechnology research and development company specializing in nucleic acid-based biomedicines. The company focuses on the development of vaccines, plasmid-encoded monoclonal antibodies, recombinant proteins, and small molecule therapeutics. Its pipeline products include GLS-1027 which treats COVID-19, nephropathy and inflammatory diseases; GLS-1200 for rhinosinusitis and COVID-19; GLS-5140 treats SFTS prophylaxis; GLS-6150 targets hepatitis C re-infection prophylaxis and others. The company collaborates with multinational pharmaceutical companies and research institutes. It operates with an additional office in Pennsylvania, the US. GeneOne Life Science is headquartered in Seoul, South Korea.

For a complete picture of GLS-5310’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.